sdominick AstraZeneca ( NASDAQ: AZN ) and Amgen ( NASDAQ: AMGN ) said that phase 2a data on their asthma biologic Tezspire (tezepelumab) indicates the treatment may be effective in treating chronic obstructive pulmonary disease (COPD). Though not statistically significant, data from the COURSE trial showed patients on Tezspire saw a 17% reduction in the annual rate of moderate or severe COPD exacerbations compared to placebo after a year. However, in patients with blood eosinophil counts BEC ≥150 cells/μL, tezepelumab led to a "nominally significant" reduction of 37% in the rate of exacerbations versus placebo.
More on Amgen, AstraZeneca Amgen Could Become A Real Contender In The Obesity Market Amgen's Q1 Earnings: Solid All Court Progress, Major Weight Loss Catalyst Pending AstraZeneca to build $1.5B ADC manufacturing plant in Singapore Biopharma M&A surges year over year in Q1 Amgen Inc. (AMGN) BofA Securities 2024 Health Care Conference (Transcript).